This phase 2b trial of a short interfering RNA that targets APOC3 showed substantive dose-dependent lowering of triglyceride levels.
The New England Journal of Medicine: Search Results in Cardiology
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
